Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Seek medical attention if the side effects become intolerable
For pure weight-loss endpoints, retatrutide outperforms semaglutide by roughly 9 percentage points at peak dose: 24.2% versus ~15% mean body-weight loss at comparable durations [3][4]
The article "3 Companies at the Forefront of the GLP-1 Pill Wars" first appeared on MarketBeat.
The question behind the question is usually: "How much longer will I be able to get compounded semaglutide at this price?" The pattern we see: patients conflate three separate timelines: Patent expiration (2031-2033 for the formulations that matter) FDA shortage list removal (expected late 2026 to Q1 2027) Generic market entry (2027 for oral, 2031-2032 for injectable, assuming no patent challenges) The timeline that affects current compounded access is number 2, not number 1
US$ 27.33
US$ 21.55
US$ 22.03
US$ 29.60
